The development of efficacious Copd therapies has historically taken a back seat to higher profile respiratory conditions such as asthma. Copd is plagued with low public awareness, poor diagnosis and suboptimal treatments, and a lack of understanding of the mechanisms underlying the disease. Such high levels of unmet need offer abundant opportunities to pharma companies.Overview of the Copd market - prevalence, unmet needs, improved understanding of the mechanisms underlying Copdstatus of the investigational drug pipeline - analysis of recently approved and newly marketed products, investigational drugs in phases II, II and IReview of developmental drugs that have failed to reach the marketDrug development strategies - successful strategies of key players in the Copd sectorSpiriva to act as catalyst for change in Copd treatment paradigmFirst PDE4 inhibitor close to market launchThe R&D path to market is littered with expensive failuresBenchmark your products against those currently on the marketEnhance your product entry and line extension strategies through a full understanding of the R&D pipeline
